产品名称

Temsirolimus - CCI 779 | Torisel

产品货号

Axon 1699 CAS [162635-04-3] MF C56H87NO16MW 1030.29 Purity: 99% Soluble in DMSO Description Specific mTOR inhibitor; a signaling protein that regulates cell growth and angiogenesis; a therapeutic for the treatment of advanced renal cell carcinoma (RCC), kidney cancer and other cancer types. References Certificates Categories Extra info X Wan et al. CCI-779 Inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/HIF-1alpha/VEGF signaling. Neoplasia 2006, 8(5), 394–401. D DelBufalo et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006, 66(11), 5549–5554. GV Thomas et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nature Medicine 2006, 12(1), 122–127. Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology Immunology mTOR PI3K-Akt-mTOR EC 2.7.11.1 Pfizer Licensed Products mTOR inhibitor Chemical name 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-Rapamycin Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [162635-04-3] Order Size Unit Price Stock 10 mg €95.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

Temsirolimus - CCI 779 | Torisel

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 1699

CAS [162635-04-3]

MF C56H87NO16
MW 1030.29

Purity: 99%
Soluble in DMSO

Temsirolimus

Description

Specific mTOR inhibitor; a signaling protein that regulates cell growth and angiogenesis; a therapeutic for the treatment of advanced renal cell carcinoma (RCC), kidney cancer and other cancer types.

X Wan et al. CCI-779 Inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/HIF-1alpha/VEGF signaling. Neoplasia 2006, 8(5), 394–401.

D DelBufalo et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006, 66(11), 5549–5554.

GV Thomas et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nature Medicine 2006, 12(1), 122–127.

Angiogenesis Cell Signaling & Oncology Immunology mTOR PI3K-Akt-mTOR EC 2.7.11.1 Pfizer Licensed Products

mTOR inhibitor

Chemical name

42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-Rapamycin

Source information

Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Parent CAS No.

[162635-04-3]

产品资料